Mylan releases statement in response to Financial Times article
Mylan N.V. recently released a statement in response to a Financial Times article entitled “HIV/Aids drug for developing world face threat of disruption.” Read More »
Mylan N.V. recently released a statement in response to a Financial Times article entitled “HIV/Aids drug for developing world face threat of disruption.” Read More »
Abbott recently announced that its molecular test, the Abbott RealTime Zika Test, has been authorized by the U.S. Food and Drug Administration (FDA). Read More »
A new Glaukos Corporation study reveals that the cost of two iStent Trabecular Micro-Bypass Stents could cost lower cumulatively in five years compared to others like the selective laster trabeculoplasty (also known as the SLT) or topical glaucoma medication. Read More »
CVS Health recently announced that it will sponsor the American Heart Association’s Go Red For Women movement and pledge to raise $10 million over the next three years to support research efforts. Read More »
NovellusDx has been given a new patent by the name of "Methods and Systems for Identifying Patient Specific Driver Mutations." Read More »
The U.S. Food and Drug Administration (FDA) has permitted the use of subcutaneous Actemra (tocilizumab) to assist adults who are receiving treatment for giant cell arteritis. Read More »
EMED Technologies Corp.'s SCIg60 Infusion System is the first Immune Globulin Subcutaneous (Human) mechanical pump infusion system to be approved by the U.S. Food and Drug Administration. Read More »
A recent publication by Lancet HIV found a link between the criminalization of drugs and the spread of HIV. Read More »
The U.S. Food and Drug Administration has given Bayer a priority review for its New Drug Application for copanlisib, a drug to be used for relapses of refractory follicular lymphoma in individuals who have had a minimum of two therapies. Read More »
Concert Pharmaceuticals Inc. has received a second request from the Federal Trade Commission for the acquisition of CTP-656, as well as other options for cystic fibrosis treatment, produced by Vertex Pharmaceuticals Inc. Read More »
Amgen announced May 18 a Biologics License Application which they submitted to the U.S. Food and Drug Administration for a migraine prevention medication. Read More »
CVS Pharmacy is launching a new campaign during the month of May, by the name of Long Live Skin. Read More »
Omnicell Inc, announced May 1 that they would be allowing patients of AcuDose-Rx Automated Dispensing Cabinets the ability to upgrade to the more specialty XT Series while using their current software. Read More »
Good Day Pharmacy COO, Vicki Einhellig took place in the recent National Community Pharmacists Association's Steering Committee Forum from April 25-26. Read More »
Amgen announced May 2 that they had signed an outcome-based refund contract with Harvard Pilgrim for Amgen's Repatha. Read More »
BiologicTx marked a year of successful transplants using its paired donation software, BiologicTx MatchGrid. Read More »
Pharmacy benefit managers are changing the way that prescriptions are filled, reducing the costs for patients and increasing the value for all involved. Read More »
Aytu BioScience Inc. has two new posters that exhibit the use of the MiOXSYS System, a tool developed by the company for determining oxidative stress in human semen. Read More »
Biologics Inc., a McKesson Specialty Health company, has been selected by Takeda Pharmaceutical Co. to be a “specialty pharmacy provider” for ALUNBRIG, a Takeda-manufactured drug for anaplastic lymphoma kinase positive metastatic non-small cell lung cancer. Read More »
The drug Kalydeco was recently approved to treat additional case of gene mutations in cystic fibrosis patients, the U.S. Food and Drug Administration reported on May 17 in a press release. Read More »